Opexa Therapeutics to Present at September Conferences

THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that Neil K. Warma, President and Chief Executive Officer, will present at three upcoming industry conferences. Details regarding these events are as follows:

Sidoti Emerging Growth Conference

• Presentation Date/Time: Wednesday, September 2, 2015 @ 10:40am EDT
• Location: Marriott Marquis in Times Square, New York, New York
• A live webcast of the Company presentation can be accessed here or via the Investor Relations section of the Company’s website at www.opexatherapeutics.com. An archive of the webcast will be available on the Company's website until December 2, 2015.

Rodman & Renshaw 17th Annual Healthcare Conference

• Presentation Date/Time: Thursday, September 10, 2015 @ 12:05pm EDT
• Location: Astor A in The St. Regis Hotel, New York, New York
• A live webcast of the Company presentation can be accessed here or via the Investor Relations section of the Company’s website at www.opexatherapeutics.com. An archive of the webcast will be available on the Company's website until December 10, 2015.

SeeThruEquity Fall Microcap Investor Conference

• Presentation Date/Time: Thursday, September 10, 2015 @ 2:30pm EDT
• Location: Convene Grand Central, New York, New York

About Opexa

Opexa is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient’s peripheral blood and reintroduced into the patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient.

For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com or follow company news on Twitter via @OpexaCEO.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150828005025/en/

Opexa Therapeutics, Inc.
Karthik Radhakrishnan, 281-775-0600
Chief Financial Officer

Source: Opexa Therapeutics, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• AI in the Courtroom Is Becoming a Malpractice Risk for Law Firms, Wisner Baum Warns
• Kutcho Copper Commences 2026 Drill Program
• EraNova Produces 50 oz Silver Bar from Silver Surprise Mini-Bulk Sample at Local Atlin Facility